Limits...
Prognostic value of histological type in stage IV ovarian carcinoma: a retrospective analysis of 223 patients.

Mizuno M, Kajiyama H, Shibata K, Mizuno K, Kawai M, Nagasaka T, Kikkawa F - Br. J. Cancer (2015)

Bottom Line: This study aimed to compare the survival of patients with serous or endometrioid tumours (S/E) and clear cell or mucinous tumours (non-S/E).The median overall survivals (OSs) of the S/E and non-S/E groups were 3.1 and 0.9 years, respectively (P<0.001).Therefore, careful management and development of new strategies are required.

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466-8550, Japan.

ABSTRACT

Background: Patients with FIGO stage IV epithelial ovarian carcinoma have a poor but non-uniform prognosis. This study aimed to compare the survival of patients with serous or endometrioid tumours (S/E) and clear cell or mucinous tumours (non-S/E).

Methods: Data for 223 patients who underwent surgery between 1987 and 2010 and were diagnosed by centralized pathology review and were retrospectively analysed. The patients included 169 with S/E tumours and 54 with non-S/E tumours.

Results: The median overall survivals (OSs) of the S/E and non-S/E groups were 3.1 and 0.9 years, respectively (P<0.001). Six patients (2.7%), all with non-S/E tumours, died within 6 weeks after the initial surgery. Multivariate OS analysis revealed that performance status, residual tumor, metastatic sites, no debulking surgery, and non-S/E tumours were independent poor prognostic factors. For patients with non-S/E tumours, prognosis was more favourable for single-organ metastasis, except for liver or distant lymph nodes, no residual tumor, and resection of metastasis (median OS: 4.1, 4.6, and 2.6 years, respectively).

Conclusions: In stage IV ovarian carcinoma, non-S/E tumours are associated with a significantly poorer prognosis and higher rates of early mortality compared to S/E tumours. Therefore, careful management and development of new strategies are required.

Show MeSH

Related in: MedlinePlus

Overall survival curves according to the initial treatment response in patients with stage IV ovarian carcinoma. S/E group, serous or endometrioid tumours; non-S/E group: clear cell, mucinous, and other tumours; CR=complete response.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4402461&req=5

fig3: Overall survival curves according to the initial treatment response in patients with stage IV ovarian carcinoma. S/E group, serous or endometrioid tumours; non-S/E group: clear cell, mucinous, and other tumours; CR=complete response.

Mentions: In terms of the response to initial treatment, CR was achieved by 73% of the 169S/E patients and by 31.4% of the 54 non-S/E patients and non-CR occurred in 37% of the S/E and 68.6% of the non-S/E patients. The proportion of patients in the non-S/E group with CR was significantly lower than that of the S/E group (P<0.001), but there was no significant difference in the CR survival curve, as shown in Figure 3A and B (median OS S/E 3.9 vs non-S/E 5.6 years, P=0.391). Disease relapsed in 119 (83.8%) of 142 patients with an initial CR. In these patients, the interval between effect assessment and recurrence ranged from 1 month to 6.4 years, and there was no difference in the median recurrence-free survival between the S/E and non-S/E groups (1.5 vs 1.4 years, respectively; P=0.74).


Prognostic value of histological type in stage IV ovarian carcinoma: a retrospective analysis of 223 patients.

Mizuno M, Kajiyama H, Shibata K, Mizuno K, Kawai M, Nagasaka T, Kikkawa F - Br. J. Cancer (2015)

Overall survival curves according to the initial treatment response in patients with stage IV ovarian carcinoma. S/E group, serous or endometrioid tumours; non-S/E group: clear cell, mucinous, and other tumours; CR=complete response.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4402461&req=5

fig3: Overall survival curves according to the initial treatment response in patients with stage IV ovarian carcinoma. S/E group, serous or endometrioid tumours; non-S/E group: clear cell, mucinous, and other tumours; CR=complete response.
Mentions: In terms of the response to initial treatment, CR was achieved by 73% of the 169S/E patients and by 31.4% of the 54 non-S/E patients and non-CR occurred in 37% of the S/E and 68.6% of the non-S/E patients. The proportion of patients in the non-S/E group with CR was significantly lower than that of the S/E group (P<0.001), but there was no significant difference in the CR survival curve, as shown in Figure 3A and B (median OS S/E 3.9 vs non-S/E 5.6 years, P=0.391). Disease relapsed in 119 (83.8%) of 142 patients with an initial CR. In these patients, the interval between effect assessment and recurrence ranged from 1 month to 6.4 years, and there was no difference in the median recurrence-free survival between the S/E and non-S/E groups (1.5 vs 1.4 years, respectively; P=0.74).

Bottom Line: This study aimed to compare the survival of patients with serous or endometrioid tumours (S/E) and clear cell or mucinous tumours (non-S/E).The median overall survivals (OSs) of the S/E and non-S/E groups were 3.1 and 0.9 years, respectively (P<0.001).Therefore, careful management and development of new strategies are required.

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, 65 Tsuruma-cho, Showa-ku, Nagoya 466-8550, Japan.

ABSTRACT

Background: Patients with FIGO stage IV epithelial ovarian carcinoma have a poor but non-uniform prognosis. This study aimed to compare the survival of patients with serous or endometrioid tumours (S/E) and clear cell or mucinous tumours (non-S/E).

Methods: Data for 223 patients who underwent surgery between 1987 and 2010 and were diagnosed by centralized pathology review and were retrospectively analysed. The patients included 169 with S/E tumours and 54 with non-S/E tumours.

Results: The median overall survivals (OSs) of the S/E and non-S/E groups were 3.1 and 0.9 years, respectively (P<0.001). Six patients (2.7%), all with non-S/E tumours, died within 6 weeks after the initial surgery. Multivariate OS analysis revealed that performance status, residual tumor, metastatic sites, no debulking surgery, and non-S/E tumours were independent poor prognostic factors. For patients with non-S/E tumours, prognosis was more favourable for single-organ metastasis, except for liver or distant lymph nodes, no residual tumor, and resection of metastasis (median OS: 4.1, 4.6, and 2.6 years, respectively).

Conclusions: In stage IV ovarian carcinoma, non-S/E tumours are associated with a significantly poorer prognosis and higher rates of early mortality compared to S/E tumours. Therefore, careful management and development of new strategies are required.

Show MeSH
Related in: MedlinePlus